The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a regulatory submission for label expansion.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).
BIOMARIN PHARMACEUTICAL INC has a stellar value proposition. NASDAQ:BMRN not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN)
jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates. Total revenue grew 16% y/y fueled by strong demand for Voxzogo, which saw a 42% jump in sales, and a steady 9% increase in its Enzyme Therapies segment. Improved profitability also played a key role, with GAAP net income soaring more than fivefold.
Looking ahead, management expects another year of double-digit revenue and earnings growth in 2025, with a projected 10% increase in total revenue at the midpoint of guidance.
Overall, the quarter reflected strong execution, with standout performances in key growth areas and clear momentum heading into the first half of 2025.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 24.6% above analysts’ consensus estimates.
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
